Aim immunotech outlines recent significant progress across clinical development pipeline and provides update on positive pre-clinical and ip developments

Company's priority oncology clinical programs continue to advance toward key milestones additional clinical trial site now open at university of nebraska for phase 2 study of ampligen® for the treatment of pancreatic cancer (amp-270) ongoing progress toward phase 1 data in clinical development program of ampligen for the treatment of early-stage triple negative breast cancer significant findings from a new analysis support the potential to identify patients with lapc that could respond better to ampligen company bolsters patent portfolio for ampligen as a potential therapy against ebola virus disease ocala, fla., june 12, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today provided an update on its ongoing clinical development programs evaluating ampligen® (rintatolimod), a dsrna and highly selective tlr3 agonist immune-modulator with broad spectrum activity.
AIM Ratings Summary
AIM Quant Ranking